臨床試驗

Safety and Clinical Performance of a Biological Matrix Used in Implant-based Breast Reconstruction

NCT：NCT05031962 · COMPLETED

NCT IDNCT05031962

狀態COMPLETED

開始日期2021-10-04

完成時間2026-09-22

SponsorMeccellis Biotech (INDUSTRY)

First posted2021-09-02

Last updated2026-10-08

簡要摘要

The general objective of the study is to confirm the medium/long-term safety and clinical performance of the CELLIS Breast membranes used in breast reconstruction and to identify emerging risks in comparison to clinical data related to other treatment modalities. The present study will be a prospective, multicentric, non-randomized and non-controlled trial involving 112 patients followed for 24 months. The study will be conducted in France in 7 investigational centres.

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。